Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02009449 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 353
- Enrollment target
NCT02009449 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 353 participants.
The verdict
NCT02009449, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 353 participants
- Enrollment target
Study Summary
This is a first-in-human, open-label, dose escalation study to evaluate the safety and tolerability of pegilodecakin in participants with advanced solid tumors, dosed daily subcutaneously as a monotherapy or in combination with chemotherapy or immunotherapy.
Interventions
- DRUG Capecitabine
- DRUG gemcitabine/nab-paclitaxel
- DRUG Pegilodecakin
- DRUG Paclitaxel or Docetaxel and Carboplatin or Cisplatin
- DRUG FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 353 participants |
| Start Date | 2013-11-15 |
| Est. Completion | 2023-07-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02009449
The ClinicalTrials.gov registry entry for NCT02009449 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 353 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Capecitabine is the first listed.
NCT02009449 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02009449 about?
NCT02009449 is a clinical study titled "A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors". This is a first-in-human, open-label, dose escalation study to evaluate the safety and tolerability of pegilodecakin in participants with advanced solid tumors, dosed daily subcutaneously as a monotherapy or in combination with chemotherapy or immunotherapy.
What is the current status of trial NCT02009449?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 353 participants. The study started on 2013-11-15. Estimated completion is 2023-07-22.
What interventions are being tested in trial NCT02009449?
The interventions under investigation include: Capecitabine (DRUG), gemcitabine/nab-paclitaxel (DRUG), Pegilodecakin (DRUG), Paclitaxel or Docetaxel and Carboplatin or Cisplatin (DRUG), FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil) (DRUG).
Who is sponsoring clinical trial NCT02009449?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.